The aggregation of Tau during the development of AD has gained further interest as a pharmaceutical target over the last 10 years, especially as clinical tests aimed at the aggregation of the Aβ amyloid peptide have regretfully not led to improved cognitive functions of patients. This evidence concerns the gene MAPT and Alzheimer disease.